Medical Devices vs Pharma: An Investing Strategy

Pharma is the powerful subsector, and medicalJ&J and others has grown more intense,
devices/technology its smaller sibling within thethey are increasingly looking to acquire small
huge healthcare industry. They are differentcompanies with promising technologies. This has
enough that the two subsectors often move inspurred a great deal of entrepreneurial growth.
opposing directions, enabling investors to stayIs there such a thing as a blockbuster medical
diversified within the booming healthcare bydevice? Except for drug-eluting stents, probably
shifting in and out of the two subsectors atnot, when you compare devices to top
appropriate times.pharmaceutical winners. But medical technology is
In a number of treatment areas, one sector canaddressing some huge markets, with big profit
take away market share from the other. Takepotential.
the huge heart disease market. While surgicalTake back pain. It's the scourge of millions with a
interventions have become increasingly minimallymarket of over $60 billion annually. Artificial disc
invasive, pharmacological interventions, includingtechnology is rapidly coming up with advances to
thrombolytics, fibrinolytics, beta blockers, statinstreat chronic back cases. Carotid stenting, which
and anti-platelet treatments are covering a widerwas approved last year, is less invasive than
spectrum of acute coronary syndromes,surgery and sales of carotid stents are anticipated
sometimes eliminating the need for surgery.to grow to $1 billion within the decade-from less
In evaluating the potential of the two sectors, itthan $100 million today. And the annual growth
must be said that there is nothing quite likerate of computer aided surgery rate is expected
getting in early on a blockbuster drug and riding itto increase from 10% in 2005 to more than 20%
to new highs. In the meantime, smart pharmain 2009.
investors stay on the lookout for news aboutAging baby boomers will aid the medical device
clinical trials that result in new indications for aboom. Age-related ailments combined with
drug, or that show a reduction in mortality, sidemedicare eligibility will expand the use of
effects, etc. Modifications in a drug that expandpacemakers, defibrillators, stents, orthopedic
target populations are also good. Often theseimplants and cochlear implants.
kinds of developments show up on TVMedical devices/technology and pharmaceuticals
commercials. Currently, through a spate ofprovide a good way to diversify within healthcare,
commercials you can witness the battle unfoldthough you must stay current on developments
over new indications for insomnia treatments, asin both fields. Of course, if you're really looking for
drug companies address the huge and growinggrowth you might turn to an even smaller
problem of sleeplessness in America.healthcare/biotech sibling- diagnostics. With
But on the whole, right now Pharma is in a bit ofapproval power over payments, healthcare
a funk, hoping for new blockbusters, while medicalproviders, in essence, control the money, and
devices/technology is more exciting, especiallythus wield enormous influence over which
minimally invasive technologies. Substantialtreatments grow share. Increasingly, healthcare
acceleration in FDA approval timelines since theproviders are looking at preventative measures to
passage of the 1997 Modernization Act, hasstave off the huge expense of treating full-blown
helped the medical device industry.diseases. And how do you prevent diseases?
As the competition among broad-based medicalEarly diagnosis. But more on that in another article.
technical companies, like Medtech, Boston Scientific